- U.S. indices recover from recent sell-offs in relative tentativeness; US100 gains 0.4%; US200 over 1%
- Tesla (TSLA.US) the strongest stock among US BigTech companies. Bitcoin rises back above $96K; Microstrategy (MSTR.US) gains over 4%
- Eli Lilly (LLY.US) loses 7% after disappointing diabetes drug sales forecasts
- Yields continue to settle at 4.8% despite a lower-than-forecast US PPI inflation release for December
Stock market tries to rebound today as US PPI report came in lower than expected, proving Wall Street a fuel to rebound ahead of tomorrow 1:30 PM GMT December CPI report. However, overall investors sentiments are still negative.
Eli Lilly stock sell-off weighs on pharmaceutical sector stocks; company presented disappointing sales forecasts for weight loss drug. The semiconductor and software sectors are gaining. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appUS PPI data for December
- PPI: 3.3% y/y; forecast 3.5% y/y; previously 3.0% y/y;
- PPI index: 0.2% m/m; forecast 0.4% m/m; previous 0.4% m/m;
- Base PPI: 3.5% y/y; forecast 3.8% y/y; previous 3.5% y/y;
- Base PPI: 0.0% m/m; forecast 0.3% m/m; previous 0.2% m/m;
- PPI excluding food/energy/transportation: 3.3% y/y; previously 3.5% y/y;
- PPI excluding food/energy/transport: 0.1% m/m; forecast 0.3% m/m; prior 0.1% m/m
- US Redbook chain store sales: 4% YoY vs 6.8% YoY previously
(US100, D1, H4 and H1 interval)
The key for the bulls now is to cross 21400 points, where the EMA50 (orange line) runs.
Source: xStation5
The US100 has returned above the 23.6 Fibonacci retracement of the August 2024 upward wave, crossing 21020 points.
Source: xStation5
Supply has definitely dominated over the past few sessions, and this trend continues in today's session as well.
Source: xStation5
Eli Lilly loses after disappointing forecasts
Eli Lilly forecast revenue for calendar 2024 of $58.0 billion to $61.0 billion, against a consensus of $58.72 billion. Weight-loss and type II diabetes drugs Mounjaro and Zepbound posted solid sales growth in Q4; Eli Lilly points to 'continued trend', forecasts revenue growth from new products. All this was not enough, however, in the context of a challenging valuation. Novo Nordisk (NOVOB.DK) is also losing more than 4% on the wave of Eli Lilly's decline.
- Lilly's preliminary Q4 2024 revenues. approx. $13.5 billion, estimate. USD 14.0 billion
- Q4 revenue from Monjuaro $3.5 billion, estimate $4.4 billion
- Zepbound revenues approx. $1.9 billion, estimate $2.2 billion
- The company reported that je drug sales in the U.S. rose 45% y/y, but previous guidance had predicted an even faster acceleration of growth in the quarter.
The market for insulin-boosting drugs grew more slowly than expected, but the company still sees healthy growth in 2025 due to the success of weight-loss drugs. The company expects Q4 revenue of $13.5 billion, about $400 below the low end of the last estimated range released in October; Fact Set estimated $13.93 billion.
In the fourth quarter, the company reported strong sales of Mounjaro and Zepbound drugs, as well as oncology, immunology and neuroscience drugs. The lower sales forecast was due to slow growth in the market for so-called incretins, which increase insulin levels. However, Eli Lilly estimates that the unfavorable dynamics are temporary, and is betting on a rebound sometime in early 2025.
Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
